440 related articles for article (PubMed ID: 34491666)
1. Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study.
Bishnoi A; Manjunath S; Kishore K; De D; Handa S; Murrell DF; Mahajan R
Indian J Dermatol Venereol Leprol; 2022; 88(2):177-183. PubMed ID: 34491666
[TBL] [Abstract][Full Text] [Related]
2. A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB).
Rogers CL; Gibson M; Kern JS; Martin LK; Robertson SJ; Daniel BS; Su JC; Murrell OGC; Feng G; Murrell DF
JAAD Int; 2021 Mar; 2():134-152. PubMed ID: 34409361
[TBL] [Abstract][Full Text] [Related]
3. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
Loh CC; Kim J; Su JC; Daniel BS; Venugopal SS; Rhodes LM; Intong LR; Law MG; Murrell DF
J Am Acad Dermatol; 2014 Jan; 70(1):89-97.e1-13. PubMed ID: 24355263
[TBL] [Abstract][Full Text] [Related]
4. Translation, cross-cultural adaptation and validation of the Quality of Life Evaluation in Epidermolysis Bullosa instrument in Brazilian Portuguese.
Cestari T; Prati C; Menegon DB; Prado Oliveira ZN; Machado MC; Dumet J; Nakano J; Murrell DF
Int J Dermatol; 2016 Feb; 55(2):e94-9. PubMed ID: 26474322
[TBL] [Abstract][Full Text] [Related]
5. Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB).
Bruckner AL; Fairclough DL; Feinstein JA; Lara-Corrales I; Lucky AW; Tolar J; Pope E
Br J Dermatol; 2018 May; 178(5):1128-1134. PubMed ID: 29341069
[TBL] [Abstract][Full Text] [Related]
6. An analysis of the prevalence of osteoporosis and osteopenia in patients with epidermolysis bullosa: A cross-sectional study.
Kang M; Chen JSC; Radjenovic M; Yang A; Feng GHY; Murrell DF
Exp Dermatol; 2021 Nov; 30(11):1675-1685. PubMed ID: 33347654
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.
Feinstein JA; Jambal P; Peoples K; Lucky AW; Khuu P; Tang JY; Lara-Corrales I; Pope E; Wiss K; Hook KP; Levin LE; Morel KD; Paller AS; McCuaig CC; Powell J; Eichenfield LF; Price H; Levy ML; Schachner LA; Browning JC; Bayliss S; Jahnke M; Shwayder T; Glick SA; Bruckner AL
JAMA Dermatol; 2019 Feb; 155(2):196-203. PubMed ID: 30586139
[TBL] [Abstract][Full Text] [Related]
8. The Birmingham Epidermolysis Bullosa Severity score: development and validation.
Moss C; Wong A; Davies P
Br J Dermatol; 2009 May; 160(5):1057-65. PubMed ID: 19434791
[TBL] [Abstract][Full Text] [Related]
9. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument.
Frew JW; Martin LK; Nijsten T; Murrell DF
Br J Dermatol; 2009 Dec; 161(6):1323-30. PubMed ID: 19681875
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in epidermolysis bullosa: Validation of the Dutch QOLEB questionnaire and assessment in the Dutch population.
Yuen WY; Frew JW; Veerman K; van den Heuvel ER; Murrell DF; Jonkman MF
Acta Derm Venereol; 2014 Jul; 94(4):442-7. PubMed ID: 24337132
[TBL] [Abstract][Full Text] [Related]
11. Translation, cultural adaptation and validation of the German Quality of Life in Epidermolysis Bullosa (QOLEB) questionnaire.
Salamon G; Strobl S; Field-Werners U; Welponer T; Murrell DF; Diem A
J Health Psychol; 2024 Feb; ():13591053231221369. PubMed ID: 38369713
[TBL] [Abstract][Full Text] [Related]
12. A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa.
Paller AS; Pope E; Rudin D; Malyala A; Ramsdell D; Johnson R; Landy H; Murrell DF;
Orphanet J Rare Dis; 2022 Aug; 17(1):314. PubMed ID: 35964087
[TBL] [Abstract][Full Text] [Related]
13. Ophthalmologic Approach in Epidermolysis Bullosa: A Cross-Sectional Study With Phenotype-Genotype Correlations.
Mellado F; Fuentes I; Palisson F; I Vergara J; Kantor A
Cornea; 2018 Apr; 37(4):442-447. PubMed ID: 29384803
[TBL] [Abstract][Full Text] [Related]
14. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex.
So JY; Fulchand S; Wong CY; Li S; Nazaroff J; Gorell ES; de Souza MP; Murrell DF; Teng JM; Chiou AS; Tang JY
Orphanet J Rare Dis; 2022 Jul; 17(1):270. PubMed ID: 35841105
[TBL] [Abstract][Full Text] [Related]
15. The severity of malnutrition in children with epidermolysis bullosa correlates with disease severity.
Manjunath S; Mahajan R; De D; Handa S; Attri S; Behera BN; Bhasin SL; Bolia R
Sci Rep; 2021 Aug; 11(1):16827. PubMed ID: 34413404
[TBL] [Abstract][Full Text] [Related]
16. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa.
Fine JD; Johnson LB; Weiner M; Suchindran C
Clin Exp Dermatol; 2004 Mar; 29(2):122-7. PubMed ID: 14987264
[TBL] [Abstract][Full Text] [Related]
17. Transcultural Validation of a Spanish Version of the Quality of Life in Epidermolysis Bullosa Questionnaire.
Villar Hernández AR; Molero Alonso F; Aguado Marín ÁJ; Posada de la Paz M
Int J Environ Res Public Health; 2022 Jun; 19(12):. PubMed ID: 35742308
[TBL] [Abstract][Full Text] [Related]
18. "Quality of Life in Epidermolysis Bullosa" and "Epidermolysis Bullosa Burden of Disease": Italian translation, cultural adaptation, and pilot testing of two disease-specific questionnaires.
Hachem ME; Diociaiuti A; Zambruno G; Samela T; Ferretti F; Carnevale C; Linertová R; Bodemer C; Murrell DF; Abeni D
Ital J Pediatr; 2024 Apr; 50(1):76. PubMed ID: 38637879
[TBL] [Abstract][Full Text] [Related]
19. Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study.
Mellerio JE; Pillay EI; Ledwaba-Chapman L; Bisquera A; Robertson SJ; Papanikolaou M; McGrath JA; Wang Y; Martinez AE; Jeffs E
Orphanet J Rare Dis; 2023 Aug; 18(1):235. PubMed ID: 37559055
[TBL] [Abstract][Full Text] [Related]
20. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa.
Jain SV; Harris AG; Su JC; Orchard D; Warren LJ; McManus H; Murrell DF
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):692-698. PubMed ID: 27580431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
